The activist hedge fund stalking GlaxoSmithKline has homed in on its vaccines business in talks with other investors.
Elliott Management is understood to have sought shareholders views on how to unlock value from the division, which contributed £7 billion towards Glaxos £34 billion sales last year and almost a third of its earnings. Glaxos vaccines business is the biggest in the world by sales and makes products including Shingrix, the blockbuster shingles shot. Reports of Elliotts talks suggest…
